Market Opportunity Target the 50,000 most severe heart failure patients eligible for cardiac assistance, with FLOWMAKER addressing a potential market segment valued at over US$5 billion, presenting a sizeable entry point for early sales and clinical adoption.

Clinical Advantage Leverage FLOWMAKER’s fully intraventricular, wireless flow acceleration, beat-by-beat synchronization, and wireless recharging to position as a less invasive, physiologic alternative to bypass surgeries, appealing to surgeons seeking innovative solutions with reduced patient risk.

Strategic Partnerships Engage with leading cardiac surgeons, electro-physiologists, and European public and private funding networks to accelerate clinical trials, reimbursement discussions, and early adopter programs across Europe, supported by EU and regional funding.

Expansion Pathway Identify adjacent markets and procedures that could benefit from wireless, beat-synchronized flow support, including expansion to other heart failure stages or surgical centers with high volumes of complex cases to scale adoption and revenue.

Financial & Investment Signals Highlight strong investor base and EU funding alignment to reassure potential customers and partners about cadence of development and potential for joint ventures, licensing, or co-development opportunities with larger medical device players.